Handelsavisen
prelaunch
Companies Healthcare NUTM.BK
NU
NUTM.BK SET (Bangkok) Pharmaceuticals

Nutrition Profess PCL

Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
13,20 %
Op margin
8,6 %
ROE
Net margin
6,6 %
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Nutrition Profess PCL is a Thai company that develops, produces, and distributes nutritional supplements and health products, primarily targeting the consumer staples and healthcare markets.

Business. Nutrition Profess PCL (NUTM.BK) is a pharmaceutical company headquartered in Thailand that operates within the Healthcare sector. The firm is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NUTM.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NUTM.BK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Nutrition Profess PCL (NUTM.BK) is a pharmaceutical company headquartered in Thailand that operates within the Healthcare sector. The firm is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Nutrition Profess PCL maintains a capital structure with 120 million shares outstanding, both basic and diluted, indicating no immediate dilution pressure from share-based compensation or convertible instruments. The company reported free cash flow of 29,926,210 THB, suggesting it generates sufficient cash to support operations and potentially fund growth initiatives. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    The company's profitability is reflected in a gross profit of 253,247,900 THB and an operating income of 25,731,130 THB. While these figures indicate a healthy gross margin, the operating margin is relatively low at 8.57%, which is below the typical range for pharmaceutical and health product companies. This suggests that the company may face cost pressures or pricing constraints in its operations.

    Nutrition Profess PCL operates in a single business segment focused on nutritional supplements and health products. The company's revenue is concentrated in this segment, with no disclosed geographic diversification. This concentration may expose the company to regional economic or regulatory risks, particularly in Thailand, where it is headquartered.

    The company's growth trajectory is not clearly defined in the available data. No forward-looking revenue guidance or historical growth rates are provided, making it difficult to assess the company's future performance. The absence of capital expenditure data beyond a small negative value of -624,570 THB suggests limited investment in new projects or expansion.

    Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the lack of going-concern language in source documents. Additionally, the company's reliance on a single business segment and geographic concentration may increase its vulnerability to market fluctuations. There is no indication of dilution pressure in the near term, as shares outstanding remain unchanged between basic and diluted counts.

    Recent events and filings are not detailed in the available data. The company's 10-K or equivalent disclosures are not accessible in the provided source documents, limiting the ability to analyze recent strategic moves or financial developments.

    Key takeaways
    • Nutrition Profess PCL generates strong gross profits but has a low operating margin, indicating potential cost or pricing pressures.
    • The company's capital structure shows no immediate dilution risk, with basic and diluted shares outstanding being equal.
    • Free cash flow is positive, suggesting the company can support operations and potentially fund growth.
    • The company's business is concentrated in a single segment and geographic region, increasing exposure to local market risks.
    • Liquidity risk cannot be assessed due to missing balance-sheet data and no going-concern language in source documents.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    202.0%
    CapEx / revenue
    -0.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    Op Margin8,6 %Above median
    Net Margin6,6 %Above median
    Capex / Rev-0,2 %Above P75
    Cash Conv2,02Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Capex To Revenue
      capital_expenditure / revenue
    Source documents
    • Nutrition Profess PCL Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NUTM.BKCanonical
    SET (Bangkok) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage